Clinical trials
Restrictive Lung Disease clinical trials
Below are recruiting restrictive lung disease clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04941326Recruiting
Spinal mobilization for breathing in Parkinson’s disease
This study tests whether a hands-on therapy to the spine can improve breathing measures in people with Parkinson’s disease. If you qualify, you would receive spinal mobilization and have your breathing assessed to see if it helps.
BoluAges 50–85 - NCT06674148RecruitingPhase 2/Phase 3
Qifangfeixian granules for connective tissue disease lung scarring
This trial tests a Chinese herbal medicine called Qifangfeixian granules for people with lung scarring (interstitial lung disease) related to connective tissue diseases (like lupus or scleroderma). It compares the medicine to a placebo to see if it helps improve breathing and lung function.
Wuhan, HubeiAges 18–80 - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Basking Ridge, New JerseyAges 18 years+ - NCT07179380RecruitingPhase 3
A study of an inhaled drug for lung disease with high blood pressure
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06855004Recruiting
Study of severe breathing problems in people with lung scarring
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
BobignyAges 18 years+ - NCT05798923RecruitingPhase 2
LAM-001 for lung scarring with high blood pressure
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
Tucson, ArizonaAges 18–80 - NCT06054854Recruiting
Lung Cancer Biomarker Study (BIRD Biobank)
This study collects blood, tissue, and other samples from people with lung nodules, suspected lung cancer, or confirmed lung cancer to find better ways to diagnose and treat the disease. By joining, you help researchers discover new biomarkers that could improve care for future patients.
ToulouseAges 18 years+ - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Phoenix, ArizonaAges 18–80 - NCT07699614Recruiting
Lung health and germs in adults in Botswana
This study looks at how the lungs and tiny organisms in the body (microbiome) work together in adults living in Botswana. It may help doctors understand how to keep lungs healthier, especially for people with or without HIV.
GaboroneAges 35 years+ - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT06986070RecruitingPhase 1
Stem cell therapy for mild to moderate COPD
This study tests whether a new type of stem cell (SMS cells) can help people with mild or moderate COPD caused by smoking or pollution. You will receive the treatment by inhalation and be followed to see if your breathing improves.
Melbourne, VictoriaAges 39–69 - NCT07140328RecruitingPhase 2
Testing a new inhaler for COPD symptoms
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
Nanchang, JiangsuAges 40–80 - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Stanford, CaliforniaAges 3 years+ - NCT07261293Recruiting
Blood flow restriction exercise for COPD patients
This study tests whether adding mild blood flow restriction to aerobic exercise can improve lung function, exercise capacity, and inflammation in people with stable COPD. You would exercise on a bike or treadmill while wearing soft cuffs on your legs to lightly restrict blood flow.
IstanbulAges 40–80 - NCT07588503RecruitingPhase 1
FES Cycling With Blood Flow Restriction for Spinal Cord Injury
This study tests a new exercise method combining electrical stimulation (FES) and controlled blood flow restriction while you cycle. It's designed to improve heart health, blood sugar control, and fitness in people with spinal cord injuries.
Toronto, OntarioAges 18–75 - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06482190RecruitingPhase 1
Safety study of an inhaled drug in healthy adults
This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.
Geelong, VictoriaAges 18–60 - NCT07482475Recruiting
COPD study for people getting lung cancer screening
This study looks at COPD in people who are already getting lung cancer screening. If you have COPD or a high risk for it, joining this observational trial may help researchers learn more about your condition.
Ann Arbor, MichiganAges 50–80 - NCT06497530RecruitingPhase 2
Lurbinectedin with serplulimab for extensive-stage SCLC maintenance
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Guangzhou, GuangdongAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06974981Recruiting
Using lung cancer screening to find and treat COPD
This study looks at how lung cancer screening can also help find and manage COPD, a lung condition that often goes undetected. If you are a current or former smoker and meet certain age and smoking history criteria, you may join to help improve screening and care for both lung cancer and COPD.
Philadelphia, PennsylvaniaAges 50–80
Hear when a new Restrictive Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for restrictive lung disease?
- Yes. Clin2 currently lists 26 recruiting restrictive lung disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a restrictive lung disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a restrictive lung disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.